Does wine consumption explain the French paradox?

Dialogues in Cardiovascular Medicine

Volumn 13, Issue 3, 2008, Pages 183-192

  de Leiris, Jöel ^a   Boucher, Francois ^a  

^a UNIV GRENOBLE ALPES   (France)

Author keywords

Alcohol; Cardiovascular protection; French paradox; Phenolic compound; Wine

Indexed keywords

ALCOHOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OMEGA 3 FATTY ACID; POLYPHENOL; PROCYANIDIN DERIVATIVE; PROTEIN KINASE C; RESVERATROL; SATURATED FATTY ACID;

ALCOHOL CONSUMPTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; DRINKING BEHAVIOR; FAT INTAKE; FRANCE; GENE ACTIVATION; GENE EXPRESSION; GRAPE JUICE; HEART INFARCTION; HEART PROTECTION; HUMAN; MORTALITY; NONHUMAN; POPULATION DIFFERENTIATION; RED WINE; REVIEW; RISK REDUCTION;

EID: 57349132602     PISSN: 12729949     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet. 1992;344:1523-1526.
2. Providência R. Cardiovascular protection from alcoholic drinks: Scientific basis of the French Paradox. Rev Port Cardiol . 2006;25:1043-1058.
3. Albert CM, Manson JE, Cook NR, et al. Moderate alcohol consumption and the risk of sudden cardiac death among US male physicians. Circulation. 1999;100:944-950.
4. Mukamal KJ, Conigrave KM, Mittleman MA, et al. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med. 2003;348:109-118.
5. De Lorgeril M, Salen P, Martin JL, et al. Wine drinking and risks of cardiovascular complications after recent acute myocardial infarction. Circulation. 2002;106:1465-1469.
6. Corder R. The Wine Diet. London, UK: Sphere; 2000:1-256.
7. St Leger AS, Cochrane AL, Moore F. Factors associated with cardiac mortality in developed countries with particular reference to the consumption of wine. Lancet. 1979;1:1017-1020.
8. Fuchs FD, Chambless LE, Folsom AR, et al. Association between alcoholic beverage consumption and incidence of coronary heart disease in whites and blacks. Am J Epidemiol. 2004;160:466-474.
9. Klatsky AL, Friedman GD, Armstrong MA, et al. Wine, liquor, beer, and mortality. Am J Epidemiol. 2003;158:585-595.
10. Grønbæk M, Deis A, Sorensen TL, et al. Mortality associated with moderate intakes of wine, beer or spirits. BMJ. 1995;310:1165-1169.
11. Gronbaek M, Becker U, Johansen D, et al. Type of alcohol consumed and mortality from all causes, coronary disease, and cancer. Ann Intern Med. 2000;133:411-419.
12. Renaud SC, Guéguen R, Siest G, et al. Wine, beer, and mortality in middle-aged men from eastern France. Arch Intern Med . 1999;159:1865-1870.
13. Mukamal KJ, Chiuve SE, Rimm EB. Alcohol consumption and risk for coronary heart disease in men with healthy lifestyles. Arch Intern Med. 2006;166:2145-2150.
14. Muntwyler J, Hennekens CH, Buring JE, et al. Mortality and light to moderate alcohol consumption after myocardial infarction. Lancet. 1998;352:1882-1885.
15. Shaper AG, Wannamethee SG. Alcohol intake and mortality in middle aged men with diagnosed coronary heart disease. Heart. 2000;83:394-399.
16. Mukamal KL, Maclue M, Muller JE, et al. Prior alcohol consumption and mortality following acute myocardial infarction. JAMA. 2001;285:1965-1970.
17. van de Wiel A, van Golde PHM, Hart HCH. Blessings of the grape. Eur J Intern Med. 2001;12:484-489.
18. Bertelli AAE. Wine, research and cardiovascular disease: instructions for use. Atherosclerosis. 2007;195:242-247.
19. Bertelli AAE, Migliori M, Panichi V, et al. Oxidative stress and inflammatory reaction modulation by white wine. Ann N Y Acad Sci. 2002;957:295-301.
20. Corder R, Mullen W, Khan NQ, et al. Oenology: Red wine procyanidins and vascular health. Nature. 2006;444:566.
21. Szmitko PE, Verma S. Antiatherogenic potential of red wine: clinician update. Am J Physiol. 2005;288:H2023-H2030.
22. Das DK, Maulik N. Resveratrol in cardioprotection: A therapeutic promise of alternative medicine. Mol Interv. 2006;6:36-47.
23. Thirunavukkarasu M. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med. 2007;43:720-729.
24. Toufektsian MC, de Lorgeril M, Nagy N, et al. Protection against myocardial infarction after long-term chronic dietary intake of plant-derived anthocyanins protects the rat heart against regional ischemia-reperfusion injury. J Nutr. 2008;138;747-752.
25. Nijveldt RJ, van Nood E, van Hoorn DEC, et al. Flavonoids: A review of probable mechanisms of action and potential applications. Am J Clin Nutr. 2001;74:418-425.
26. 3 receptor activation. Am J Physiol. 2005;288:H328-H335.
27. Das S, Tosaki A, Bagchi D, et al. Potentiation of a survival signal in the ischemic heart by resveratrol through p38 mitogen-activated protein kinase/mitogen- and stress-activated protein kinase 1/camp response element-binding protein signaling. J Pharmacol Exp Ther. 2006;317:980-988.
28. Sparagna GC, Jones CE, Hickson-Bick DL. Attenuation of fatty acid-induced apoptosis by low-dose alcohol in neonatal rat cardiomyocytes. Am J Physiol. 2004;287:H2209-H2215.
29. Su CY, Chong KY, Owen OE, et al. Constitutive and inducible HSP70s are involved in oxidative resistance evoked by heat shock or ethanol. J Mol Cell Cardiol. 1998;30:587-598.
30. Sato M, Maulik N, Das DK. Cardioprotection with alcohol: Role of both alcohol and polyphenolic antioxidants. Ann N Y Acad Sci . 2002;957:122-135.
31. Guiraud A, de Lorgeril M, Boucher FR, et al. Cardioprotective effect of chronic low dose ethanol drinking. Insights into the concept of ethanol preconditioning. J Mol Cell Cardiol. 2004; 36:561-566.
32. de Lorgeril M, Salen P, Martin JL, et al. Interactions of wine drinking with omega-3 fatty acids in patients with coronary heart disease. Am Heart J. 2008;155:175-181.
33. Guiraud A, de Lorgeril M, Zeghichi S, et al. Interactions of ethanol drinking with n-3 fatty acids in rats: Potential consequences for the cardiovascular system. Br J Nutr. 2008. In press.
34. Lucas DL, Brown RA, Wassef M, et al. Alcohol and the cardiovascular system. J Am Coll Cardiol. 2005;45:1916-1924.
35. Rakotovao AN, Berthonneche C, Guiraud A, et al. Ethanol, wine, and experimental cardioprotection in ischemia-reperfusion: Role of the prooxidant/antioxidant balance. Antioxid Redox Signal. 2004;6:431-438.
36. Inagaki K, Mochly-Rosen D. δ-PKC-mediated activation of -̇PKC in ethanol-induced cardiac protection from ischemia. J Mol Cell Cardiol. 2005;39:203-211.
37. Niccoli G, Altamura L, Fabretti A, et al. Ethanol abolishes ischemic preconditioning in humans. J Am Coll Cardiol. 2008;51:271-275.
38. Manach C, Williamson G, Morand C, et al. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr. 2005;81(suppl 1): 230S-242S.
39. Dell'Agli M, Busciala A, Bosisio E. Vascular effects of wine polyphenols. Cardiovasc Res. 2004;63:593-602.
40. Sacanella E, Vázquez-Agell M, Mena MP, et al. Down-regulation of adhesion molecules and other inflammatory biomarkers after moderate wine consumption in healthy women: A randomized trial. Am J Clin Nutr. 2007;86:1463-1469.
41. Estruch R, Sacanella E, Badia E, et al. Different effects of red wine and gin consumption on inflammatory biomarkers of atherosclerosis: A prospective randomized cross-over trial. Effects of wine on inflammatory markers. Atherosclerosis. 2004; 175:117-123.
42. Ferrali M, Signorini C, Caciotti B, et al. Protection against oxidative damage of erythrocyte membrane by the flavonoid quercetin and its relation to iron chelating activity. FEBS Lett. 1997;416:123-129.
43. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: The in-vivo evidence. Nat Rev Drug Discov. 2006;5:493-506.
44. Tauchert M. Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable NYHA class-III heart failure. Am Heart J. 2002;143:910-915.
45. Chatterjee SS, Koch E, Jaggy H, et al. In vitro and in vivo studies on the cardioprotective action of oligomeric procyanidins in a Crataegus extract of leaves and blooms. Arzneimittelforschung. 1997;47:821-825.
46. Al-Makdessi A, Sweidan H, Jacob R. Effect of oligomer procyanidins on reperfusion arrhythmias and lactate dehydrogenase release in the isolated rat heart. Arzneimittelforschung. 2006;56:317-321.
47. Ferrières J. The French paradox: Lessons for other countries. Heart. 2004;90:107-111.
48. Mukamal KJ, Maclure M, Muller JE, et al. Binge drinking and mortality after acute myocardial infarction. Circulation. 2005;112:3839-3845.
49. WHO-World Health Report 2002. Reducing risks, promoting healthy life. Geneva Switzerland: http://www.whoint/whr/2002/en/ index.html Accessed July 28, 2008.
50. WHO-Global Status Report on Alcohol. Geneva, Switzerland: http://www.who.int/substance_abuse/publications/alcohol/en/index.html 2004:46-48. Accessed July 28, 2008.